RecruitingPhase 4NCT07045935

Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment

Studying Functioning pituitary adenoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Hospital, Basel, Switzerland
Principal Investigator
Cihan Atila, Dr.
University Hospital Basel, Dept. of Endocrinology, Metabolism & Diabetes
Intervention
Cabergoline (Dopamine Agonist)(drug)
Enrollment
60 enrolled
Eligibility
18 years · All sexes
Timeline
2025 – 2029

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07045935 on ClinicalTrials.gov

Other trials for Functioning pituitary adenoma

Additional recruiting or active studies for the same condition.

See all trials for Functioning pituitary adenoma →

← Back to all trials